{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:05:12Z","timestamp":1779887112568,"version":"3.53.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K13564"],"award-info":[{"award-number":["24K13564"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Forensic Toxicol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s11419-025-00733-4","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T16:38:53Z","timestamp":1752683933000},"page":"61-71","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The determination of the novel insomnia medication lemborexant using a validated liquid chromatography\u2013tandem\u00a0mass spectrometry method, and its quantitation in clinical and forensic samples"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7947-2999","authenticated-orcid":false,"given":"Brian","family":"Waters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Matsusue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Kashiwagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Ikematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichi","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"733_CR1","unstructured":"Eisai Inc (2019) Highlights of prescribing information for DAYVIGO (lemborexant) tablets. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212028s000lbl.pdf. Accessed Apr 2025"},{"key":"733_CR2","unstructured":"Eisai Inc (2019) U.S. FDA approves EISAI\u2019S DAYVIGOTM (lemborexant) for treatment of insomnia in adult patients. https:\/\/www.eisai.com\/news\/2019\/news201993.html. Accessed Apr 2025"},{"issue":"4","key":"733_CR3","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40265-020-01276-1","volume":"80","author":"LJ Scott","year":"2020","unstructured":"Scott LJ (2020) Lemborexant: first approval. Drugs 80(4):425\u2013432. https:\/\/doi.org\/10.1007\/s40265-020-01276-1","journal-title":"Drugs"},{"issue":"6","key":"733_CR4","doi-asserted-by":"publisher","first-page":"zsz076","DOI":"10.1093\/sleep\/zsz076\/5421821","volume":"42","author":"CT Beuckmann","year":"2019","unstructured":"Beuckmann CT, Ueno T, Nakagawa M, Suzuki M, Akasofu S (2019) Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep\/wake regulation. Sleep 42(6):zsz076. https:\/\/doi.org\/10.1093\/sleep\/zsz076\/5421821","journal-title":"Sleep"},{"key":"733_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000514963","volume":"45","author":"Y Sun","year":"2021","unstructured":"Sun Y, Tisdale RK, Kilduff TS (2021) Hypocretin\/orexin receptor pharmacology and sleep phases. Front Neurol Neurosci 45:22\u201337. https:\/\/doi.org\/10.1159\/000514963","journal-title":"Front Neurol Neurosci"},{"key":"733_CR6","unstructured":"Eisai Inc (2020) DAYVIGO\u2122 (lemborexant) approved for treatment of insomnia in Japan. https:\/\/www.eisai.com\/news\/2020\/news202005.html. Accessed Apr 2025"},{"key":"733_CR7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.sleep.2021.01.048","volume":"80","author":"J Yardley","year":"2021","unstructured":"Yardley J, K\u00e4rpp\u00e4 M, Inoue Y, Pinner K, Perdomo C, Ishikawa K, Filippov G, Kubota N, Moline M (2021) Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial. Sleep Med 80:333\u2013342. https:\/\/doi.org\/10.1016\/j.sleep.2021.01.048","journal-title":"Sleep Med"},{"key":"733_CR8","doi-asserted-by":"publisher","first-page":"113359","DOI":"10.1016\/j.jpba.2020.113359","volume":"187","author":"Y Mano","year":"2020","unstructured":"Mano Y, Ueno T, Hotta K (2020) Establishment of a simultaneous assay for lemborexant, a novel dual orexin receptor antagonist, and its three metabolites, and its application to a clinical protein binding study. J Pharm Biomed Anal 187:113359. https:\/\/doi.org\/10.1016\/j.jpba.2020.113359","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"733_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1124\/dmd.120.000229","volume":"49","author":"T Ueno","year":"2021","unstructured":"Ueno T, Ishida T, Aluri J, Suzuki M, Beuckmann CT, Kameyama T, Asakura S, Kusano K (2021) Disposition and metabolism of [14C]lemborexant in healthy human subjects and characterization of its circulating metabolites. Drug Metab Dispos 49(1):31\u201338. https:\/\/doi.org\/10.1124\/dmd.120.000229","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"733_CR10","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/JCP.0000000000001562","volume":"42","author":"I Landry","year":"2022","unstructured":"Landry I, Hall N, Alur J, Filippov G, Reyderman L, Setnik B, Henningfield J, Moline M (2022) Acute cognitive effects of the dual orexin receptor antagonist lemborexant compared with suvorexant and zolpidem in recreational sedative users. J Clin Psychopharmacol 42(4):374\u2013382. https:\/\/doi.org\/10.1097\/JCP.0000000000001562","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"733_CR11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/JCP.0000000000001561","volume":"42","author":"I Landry","year":"2022","unstructured":"Landry I, Hall N, Aluri J, Filippov G, Reyderman L, Setnik B, Henningfield J, Moline M (2022) Abuse potential of lemborexant, a dual orexin receptor antagonist, compared with zolpidem and suvorexant in recreational sedative users. J Clin Psychopharmacol 42(4):365\u2013373. https:\/\/doi.org\/10.1097\/JCP.0000000000001561","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"733_CR12","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1177\/02698811221080459","volume":"36","author":"I Landry","year":"2022","unstructured":"Landry I, Hall N, Aluri J, Filippov G, Setnik B, Dayal S, Reyderman L, Moline M (2022) Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: a randomized, placebo-controlled crossover study. J Psychopharmacol 36(6):745\u2013755. https:\/\/doi.org\/10.1177\/02698811221080459","journal-title":"J Psychopharmacol"},{"issue":"2","key":"733_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/cpdd.817","volume":"10","author":"I Landry","year":"2021","unstructured":"Landry I, Nakai K, Ferry J, Aluri J, Hall N, Lalovic B, Moline ML (2021) Pharmacokinetics, pharmacodynamics, and safety of the dual orexin receptor antagonist lemborexant: findings from single-dose and multiple-ascending-dose phase 1 studies in healthy adults. Clin Pharmacol Drug Dev 10(2):153\u2013165. https:\/\/doi.org\/10.1002\/cpdd.817","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"4","key":"733_CR14","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00213-023-06320-y","volume":"240","author":"M Moline","year":"2023","unstructured":"Moline M, Asakura S, Beuckman C, Landry I, Setnik B, Ashworth J, Henningfield JE (2023) The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act. Psychopharmacology 240(4):699\u2013711. https:\/\/doi.org\/10.1007\/s00213-023-06320-y","journal-title":"Psychopharmacology"},{"issue":"7","key":"733_CR15","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/jat\/bkaa072","volume":"44","author":"S Sofalvi","year":"2020","unstructured":"Sofalvi S, Lavins ES, Kaspar CK, Michel HM, Mitchell-Mata CL, Huestis MA, Apollonio LG (2020) Development and validation of an LC\u2013MS\u2013MS method for the detection of 40 benzodiazepines and three Z-drugs in blood and urine by solid-phase extraction. J Anal Toxicol 44(7):708\u2013717. https:\/\/doi.org\/10.1093\/jat\/bkaa072","journal-title":"J Anal Toxicol"},{"issue":"2","key":"733_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3390\/toxics11020109","volume":"11","author":"M Iqbal","year":"2023","unstructured":"Iqbal M, Alshememry A, Imam F, Kalam MA, Akhtar A, Ali EA (2023) UPLC\u2013MS\/MS based identification and quantification of a novel dual orexin receptor antagonist in plasma samples by validated SWGTOX Guidelines. Toxics 11(2):109. https:\/\/doi.org\/10.3390\/toxics11020109","journal-title":"Toxics"},{"key":"733_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkaf032","author":"MM Gomonit","year":"2025","unstructured":"Gomonit MM, Skillman BN (2025) Quantification of daridorexant, lemborexant and suvorexant in whole blood using liquid chromatography\u2013tandem mass spectrometry. J Anal Toxicol. https:\/\/doi.org\/10.1093\/jat\/bkaf032 (Online ahead of print)","journal-title":"J Anal Toxicol"},{"issue":"1","key":"733_CR18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11419-024-00700-5","volume":"43","author":"A Nitta","year":"2025","unstructured":"Nitta A, Shima N, Kamata H, Wada M, Matsumoto K, Kakehashi H, Nakano-Fujii S, Matsuta S, Kamata T, Katagi M, Sato T, Nishioka H (2025) Incorporation of suvorexant and lemborexant into hair and their distributions after a single intake. Forensic Toxicol 43(1):97\u2013107. https:\/\/doi.org\/10.1007\/s11419-024-00700-5","journal-title":"Forensic Toxicol"},{"issue":"1","key":"733_CR19","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1002\/pcn5.62","volume":"2","author":"J Saito","year":"2023","unstructured":"Saito J, Ishii M, Sandaiji N, Yamaguchi K, Suzuki T, Yakuwa N, Yamatani A, Tachibana Y, Sago H, Murashima A (2023) Lemborexant levels in maternal serum, cord blood, and breast milk during pregnancy and lactation: a case report. PCN Rep 2(1):e62. https:\/\/doi.org\/10.1002\/pcn5.62","journal-title":"PCN Rep"},{"issue":"1","key":"733_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/jad.jad_4_25","volume":"14","author":"D Katto","year":"2025","unstructured":"Katto D, Ito H, Kobayashi D (2025) Lemborexant overdose: a case report. J Acute Dis 14(1):3. https:\/\/doi.org\/10.4103\/jad.jad_4_25","journal-title":"J Acute Dis"},{"key":"733_CR21","doi-asserted-by":"publisher","first-page":"102527","DOI":"10.1016\/j.legalmed.2024.102527","volume":"71","author":"G Yamasaki","year":"2024","unstructured":"Yamasaki G, Ueno Y, Takahashi M, Kondo T (2024) Fatal acute lemborexant Poisoning: an autopsy case report. Leg Med (Tokyo) 71:102527. https:\/\/doi.org\/10.1016\/j.legalmed.2024.102527","journal-title":"Leg Med (Tokyo)"},{"issue":"2","key":"733_CR22","first-page":"179","volume":"39","author":"N Eto","year":"2012","unstructured":"Eto N, Kitamura T, Tanaka K, Ishikura H, Nishimura R (2012) Characteristics of suicidal patients admitted to the emergency unit; retrospective study on the first attempt and repetition of suicide attempt. Med Bull Fukuoka Univ 39(2):179\u2013189","journal-title":"Med Bull Fukuoka Univ"},{"issue":"4","key":"733_CR23","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1002\/npr2.12492","volume":"44","author":"M Masuda","year":"2024","unstructured":"Masuda M, Waters B, Gotoh L, Nakamura Y, Kato Y, Nabeshima S, Kubo S, Eto N, Kawasaki H (2024) Qualitative analysis of blood from patients engaging in deliberate self-harm: differences between prescribed and detected drugs. Neuropsychopharmacol Rep 44(4):809\u2013822. https:\/\/doi.org\/10.1002\/npr2.12492","journal-title":"Neuropsychopharmacol Rep"},{"key":"733_CR24","unstructured":"Waters B, Arao Y, Imoto E (2021) Screening and semi-quantitation by LC\/MS\/MS in whole blood using rapid Tox screening. Shimadzu application notes. https:\/\/www.shimadzu.com\/an\/sites\/shimadzu.com.an\/files\/pim\/pim_document_file\/applications\/application_note\/14426\/an_01-00255-en.pdf. Accessed Apr 2025"},{"issue":"7","key":"733_CR25","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1093\/jat\/bkt054","volume":"37","author":"Scientific Working Group for Forensic Toxicology","year":"2013","unstructured":"Scientific Working Group for Forensic Toxicology (2013) Scientific Working Group for Forensic Toxicology (SWGTOX) standard practices for method validation in forensic toxicology. J Anal Toxicol 37(7):452\u2013474. https:\/\/doi.org\/10.1093\/jat\/bkt054","journal-title":"J Anal Toxicol"},{"key":"733_CR26","unstructured":"AAFS Standards Board (2019) Standard practices for method validation in forensic toxicology. https:\/\/www.asbstandarrdsboard.org. Accessed Apr 2025"},{"issue":"4","key":"733_CR27","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/jat\/bkx001","volume":"41","author":"B Desharnais","year":"2017","unstructured":"Desharnais B, Camirand-Lemyre F, Mireault P, Skinner CD (2017) Procedure for the selection and validation of a calibration model I-description and application. J Anal Toxicol 41(4):261\u2013268. https:\/\/doi.org\/10.1093\/jat\/bkx001","journal-title":"J Anal Toxicol"},{"issue":"8","key":"733_CR28","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1093\/jat\/bkac040","volume":"46","author":"S Sofalvi","year":"2022","unstructured":"Sofalvi S, Schueler HE, Abonamah JV (2022) Expansion of the EZSTATSG1 microsoft excel tool for ANSI\/ASB Standard 036 method validation by the addition of weighted quadratic external calibration models utilizing five-, six- or seven-point curves. J Anal Toxicol 46(8):925\u2013931. https:\/\/doi.org\/10.1093\/jat\/bkac040","journal-title":"J Anal Toxicol"},{"issue":"4","key":"733_CR29","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/jat\/bkaa107","volume":"45","author":"D Mantinieks","year":"2021","unstructured":"Mantinieks D, Gerostamoulos D, Glowacki L, Di Rago M, Schumann J, Woodford NW, Drummer OH (2021) Postmortem drug redistribution: a compilation of postmortem\/antemortem drug concentration ratios. J Anal Toxicol 45(4):368\u2013377. https:\/\/doi.org\/10.1093\/jat\/bkaa107","journal-title":"J Anal Toxicol"},{"key":"733_CR30","unstructured":"Hepler BR, Isenschmid DS, Schmidt CJ (2004) Postmortem redistribution: practical considerations in death investigation. Presented at: American Academy of Forensic Sciences Annual Meeting, Dallas, TX. https:\/\/www.aafs.org\/sites\/default\/files\/media\/documents\/AAFS-2004-K14.pdf. Accessed June 2025"},{"issue":"4","key":"733_CR31","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/jat\/bkx110","volume":"42","author":"B Waters","year":"2018","unstructured":"Waters B, Hara K, Ikematsu N, Takayama M, Matsusue A, Kashiwagi M, Kubo S (2018) Tissue distribution of suvorexant in three forensic autopsy cases. J Anal Toxicol 42(4):276\u2013283. https:\/\/doi.org\/10.1093\/jat\/bkx110","journal-title":"J Anal Toxicol"},{"key":"733_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s11419-024-00706-z","author":"M Wada","year":"2024","unstructured":"Wada M, Kamata H, Shima N, Nitta A, Kakehashi H, Fujii S, Matsuta S, Kamata T, Katagi M, Nishioka H (2024) Urinary excretion profiles of the orexin receptor antagonist suvorexant and its metabolites. Forensic Toxicol. https:\/\/doi.org\/10.1007\/s11419-024-00706-z (Online ahead of print)","journal-title":"Forensic Toxicol"}],"container-title":["Forensic Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11419-025-00733-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11419-025-00733-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11419-025-00733-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T06:46:08Z","timestamp":1769755568000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11419-025-00733-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["733"],"URL":"https:\/\/doi.org\/10.1007\/s11419-025-00733-4","relation":{},"ISSN":["1860-8965","1860-8973"],"issn-type":[{"value":"1860-8965","type":"print"},{"value":"1860-8973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare with respect to this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The collection of blood samples from human patients in this study was approved by the Fukuoka University Medical Ethics Committee (U20-802) following the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}